Medicine to treat lymphatic cancer will have subcutaneous version
?Posted by: Attila Lemos ?April 17, 2016 ?0
Medicine to treat lymphatic cancer will have subcutaneous version to minimize administration time. The new method allows the application of targeted therapy occurs in minutes.
linfoma_nao_hodgkin The course of treatment can transform the reality of patients with non-Hodgkin's lymphoma, an aggressive malignant lymphatic tumor that affects from children to the elderly. In Brazil, this type of cancer is responsible for killing more than 4000 people a year and have more than 10,000 new cases of the disease in 2016¹, according to the INCA.
Depending on the stage of the disease, treatment usually includes combination chemotherapy, radiotherapy and targeted therapy. However, the use of such therapeutic allies can subject the patient to a stressful and time consuming routine, due to the long time needed for the medication infusion. To decrease the therapeutic session, researchers at Roche, a world leader in health innovation, have created a new method of administration of rituximab drug, commercially known as MabThera a prescription drug. The new option allows the subcutaneous administration of the product, thereby lowering the drug administration period of about 2.5 hours to about 5 minutes.
Recently approved by ANVISA (National Health Surveillance Agency), the SC MabThera (rituximab subcutaneous) is the first monoclonal antibody of high complexity for treating lymphomas available in the subcutaneous version in the country. According to the SparkThera and Sabrina studies conducted in several countries, including Brazil, patients who used the subcutaneous version felt less worn and more comfortable with the application, feeling less pain and spending less time in clinics / hospitals.
According Lenio Alvarenga, medical director of Roche Farma Brazil, reducing the physical and psychological strain of the patient may considerably improve the treatment as a whole. "We know that the entire patient well-being is a key component of clinical best possible outcome for a patient. The arrival of MabThera SC is the constant pursuit of innovation by Roche, is bringing treatments for unmet medical needs or improving forms of treatment to help improve the lives of patients around the world, "he says.
Never argue with a fool, for after awhile, it becomes difficult to determine which is the fool.
